Biosimilars and emerging modalities using novel diol-linked size exclusion columns

Size exclusion chromatography (SEC) is the largest analytical liquid chromatography (LC) market for biotherapeutics, and continues to be an important workflow in aggregate analysis of biopharma therapeutic platforms.

In this webinar, join Dr. Helen Whitby, senior product manager for biopharmaceuticals LC at Phenomenex, as she explores the applicability of the new diol-link size exclusion column, bioZen™ dSEC-2, for the effective analysis of biosimilars, antibody–drug conjugates (ADCs) and oligonucleotides.

Key learning objectives

• Find out more about SEC
• Explore top tips on how to be successful with ultra-performance liquid chromatography (UPLC) and high-performance liquid chromatography (HPLC) SEC
• Understand more about the analysis of biosimilars by size exclusions
• Learn about SEC nuances for the analysis of emerging modalities

Who should attend?

• Scientists looking to improve their SEC
• Scientists who want to learn more about column selection, specifically for biosimilars and emerging modalities

Presenter: Dr. Helen Whitby (Senior Product Manager – Bioseparations, Phenomenex)

Helen has a Ph.D. in synthetic, organic, and analytical chemistry from the University of Manchester, United Kingdom, and has worked at Phenomenex for the last 15 years specializing in HPLC and Bioseparations.

Presenter: Dr. Carrie Haslam (Associate Editor, SelectScience)

Dr. Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Materials Science, Alzheimer’s disease and Clinical Diagnostics. Carrie completed a Ph.D. from The University of Plymouth, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.